News Sentiment

UNCY sentiment intelligence

Unicycive Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 44 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.21 Week of 10 Jul 2026
Weighted tone 44/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-9.1% over one week, -28.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -9.1% Price reacting lower
Trend fit Trend inactive -28.1% over four weeks
Fair value -24.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 33
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 9
GlobeNewswire 6
simplywall.st 5
TradingView 4
Finviz 3
Stocktwits 2
Reuters 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 16
Regulatory and legal 6
Analyst action 2
Balance sheet 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Reuters Direct company coverage

US FDA declines to approve Unicycive's kidney disease drug

The U.S. FDA has declined to approve Unicycive Therapeutics' drug oxylanthanum carbonate (OLC) for chronic kidney disease patients due to deficiencies at a third-party manufacturing facility. This marks a second setback for the company, although the FDA had no concerns about the

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 11:12
Source
Reuters